Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9383049 | 1.00 | CTSK (0.39) | CTSKARNR1H2MEN1ALDH1A1 | |
| SCHEMBL25866969 | 1.00 | CTSK (0.39) | CTSKARNR1H2MEN1ALDH1A1 | |
| SCHEMBL5431465 | 1.00 | CTSK (0.39) | CTSKARNR1H2MEN1ALDH1A1 | |
| SCHEMBL5431463 | 1.00 | CTSK (0.39) | CTSKARNR1H2MEN1ALDH1A1 | |
| SCHEMBL7879740 | 0.86 | MEN1 (0.39) | CTSKARMEN1ALDH1A1MAPT | |
| SCHEMBL7879359 | 0.86 | MEN1 (0.39) | CTSKARMEN1ALDH1A1MAPT | |
| SCHEMBL15935560 | 0.86 | HSD17B10 (0.39) | CTSKARNR1H2MEN1ALDH1A1 | |
| SCHEMBL31001802 | 0.85 | CTSK (0.40) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31001833 | 0.85 | CTSK (0.40) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31068999 | 0.85 | CTSK (0.40) | CTSKMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-3966205-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-16 | — | — | EP | disclosed |
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | CTSK 2291/4885AR 3755/4885NR1H2 8/4885 |
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | HDGF, HAVCR2, FABP1 | CTSK 2284/4885AR 4173/4885NR1H2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.